Shares of Regenxbio Inc (NASDAQ:RGNX) traded down 7.8% during trading on Monday following insider selling activity. The stock traded as low as $48.71 and last traded at $50.39. 1,286,960 shares changed hands during mid-day trading, an increase of 137% from the average session volume of 543,849 shares. The stock had previously closed at $54.65.

Specifically, CEO Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $47.29, for a total transaction of $709,350.00. Following the completion of the transaction, the chief executive officer now directly owns 261,000 shares in the company, valued at $12,342,690. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Curran Simpson sold 43,832 shares of Regenxbio stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $50.08, for a total value of $2,195,106.56. Following the transaction, the senior vice president now owns 47,950 shares of the company’s stock, valued at $2,401,336. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 99,200 shares of company stock valued at $5,231,952. 16.90% of the stock is owned by company insiders.

Several research analysts recently weighed in on the company. BidaskClub cut Regenxbio from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Zacks Investment Research upgraded Regenxbio from a “hold” rating to a “buy” rating and set a $50.00 price target for the company in a research report on Tuesday, February 5th. Finally, Chardan Capital reiterated a “buy” rating and set a $127.50 price target on shares of Regenxbio in a research report on Friday, January 4th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company’s stock. Regenxbio presently has an average rating of “Buy” and a consensus target price of $77.97.

The stock has a market cap of $1.84 billion, a P/E ratio of 22.10 and a beta of 0.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 15.24 and a quick ratio of 15.24.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported $0.11 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.43. Regenxbio had a return on equity of 22.33% and a net margin of 45.74%. Analysts forecast that Regenxbio Inc will post -3.22 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC raised its stake in shares of Regenxbio by 37.4% during the third quarter. SG Americas Securities LLC now owns 3,422 shares of the biotechnology company’s stock valued at $258,000 after acquiring an additional 931 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Regenxbio by 12.6% during the third quarter. Bank of New York Mellon Corp now owns 359,415 shares of the biotechnology company’s stock worth $27,136,000 after buying an additional 40,085 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Regenxbio by 571.8% during the third quarter. Dimensional Fund Advisors LP now owns 124,769 shares of the biotechnology company’s stock worth $9,420,000 after buying an additional 106,198 shares during the last quarter. United Services Automobile Association raised its stake in Regenxbio by 203.3% during the third quarter. United Services Automobile Association now owns 12,286 shares of the biotechnology company’s stock worth $928,000 after buying an additional 8,235 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Regenxbio by 113.5% during the third quarter. Renaissance Technologies LLC now owns 286,500 shares of the biotechnology company’s stock worth $21,631,000 after buying an additional 152,300 shares during the last quarter. Institutional investors and hedge funds own 82.18% of the company’s stock.

WARNING: “Regenxbio (RGNX) Stock Price Down 7.8% on Insider Selling” was first posted by Marea Informative and is owned by of Marea Informative. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.mareainformativa.com/news/2019/04/24/regenxbio-rgnx-stock-price-down-7-8-on-insider-selling.html.

Regenxbio Company Profile (NASDAQ:RGNX)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.